Securian Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
  Maintained
  Sold
  | Quarter | Market Value | Status | Shares | Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
| 2025 Q3 | $4.82M | Sell |  | |||||
| 2025 Q2 | $5.98M | Sell |  | |||||
| 2025 Q1 | $6.59M | Sell |  | |||||
| 2024 Q4 | $5.56M | Sell |  | |||||
| 2024 Q3 | $6.62M | Sell |  | |||||
| 2024 Q2 | $6.93M | Sell |  | |||||
| 2024 Q1 | $6.34M | Sell |  | |||||
| 2023 Q4 | $6.64M | Sell |  | |||||
| 2023 Q3 | $6.43M | Sell |  | |||||
| 2023 Q2 | $7.61M | Sell |  | |||||
| 2023 Q1 | $6.9M | Buy |  | |||||
| 2022 Q4 | $6.28M | Buy |  | |||||
| 2022 Q3 | $6.23M | Buy |  | |||||
| 2022 Q2 | $6M | Hold |  | |||||
| 2022 Q1 | $5.56M | Sell |  | |||||
| 2021 Q4 | $4.73M | Sell |  | |||||
| 2021 Q3 | $4.07M | Sell |  | |||||
| 2021 Q2 | $4.56M | Sell |  | |||||
| 2021 Q1 | $4.92M | Sell |  | |||||
| 2020 Q4 | $5.59M | Sell |  | |||||
| 2020 Q3 | $6.55M | Sell |  | |||||
| 2020 Q2 | $7.11M | Sell |  | |||||
| 2020 Q1 | $6.11M | Sell |  | |||||
| 2019 Q4 | $5.71M | Sell |  | |||||
| 2019 Q3 | $4.55M | Sell |  | |||||
| 2019 Q2 | $4.96M | Buy |  | |||||
| 2019 Q1 | $4.91M | Buy |  | |||||
| 2018 Q4 | $4.39M | Buy |  | |||||
| 2018 Q3 | $5.08M | Buy |  | |||||
| 2018 Q2 | $4.47M | Buy |  | |||||
| 2018 Q1 | $4.26M | Buy |  | |||||
| 2017 Q4 | $3.88M | Buy |  | |||||
| 2017 Q3 | $3.88M | Buy |  | |||||
| 2017 Q2 | $3.25M | Buy |  | |||||
| 2017 Q1 | $2.73M | Buy |  | |||||
| 2016 Q4 | $1.83M | Buy |  | |||||
| 2016 Q3 | $2.14M | Buy |  | |||||
| 2016 Q2 | $2.08M | Buy |  | |||||
| 2016 Q1 | $1.91M | Buy |  | |||||
| 2015 Q4 | $2.98M | Buy |  | |||||
| 2015 Q3 | $2.4M | Sell |  | |||||
| 2015 Q2 | $2.86M | Buy |  | |||||
| 2015 Q1 | $2.67M | Buy |  | |||||
| 2014 Q4 | $2.59M | Buy |  | |||||
| 2014 Q3 | $2.36M | Buy |  | |||||
| 2014 Q2 | $1.99M | Buy |  | |||||
| 2014 Q1 | $1.48M | Buy |  | |||||
| 2013 Q4 | $1.54M | Buy |  | |||||
| 2013 Q3 | $1.56M | Sell |  | |||||
| 2013 Q2 | $2.65M | Buy |  |